国际eDelphi研究:就银屑病患者甲氨蝶呤给药方案达成共识
该研究采用改良eDelphi法,于2020年9月至2021年3月开展3轮调查,180名全球参与者完成全部轮次,就21项甲氨蝶呤给药方案提案进行投票。最终20项提案达成共识,共识可能有助于统一银屑病患者的甲氨蝶呤治疗。
要点
- 180名参与者完成3轮调查,来自全球,55名(30.6%)来自非西方国家。
- 21项提案中20项达成共识,共识定义为不同意票低于15%。
- 叶酸和儿童等亚群给药方案仍需更多研究。
核心结论
- 在该eDelphi共识研究中,21项关于银屑病患者甲氨蝶呤给药的提案中有20项达成共识。
- 该共识可能潜在用于统一银屑病患者的甲氨蝶呤治疗。
- 仍需更多研究,尤其是关于叶酸以及儿童和脆弱患者等亚群甲氨蝶呤给药的提案。
研究设计与样本
- 研究采用改良eDelphi程序的调查法,于2020年9月至2021年3月进行3轮调查,由阿姆斯特丹大学医学中心开发并分发。
- 共251名参与者,其中180名(71.7%)完成全部3轮调查,58名参与者(23.1%)参加了2021年6月的共识会议。
- 参与者通过皮肤炎症与银屑病国际网络和欧洲皮肤病与性病学会于2020年6月招募,除皮肤科医生/住院医师外无特定参与标准。
- 参与者主要在大学医院工作(97名,53.9%),163名(91.6%)有超过10年使用甲氨蝶呤治疗银屑病的经验。
主要发现
- 第1轮对11项提案达成共识,第2轮对3项提案达成共识,第3轮对2项提案达成共识。
- 共识会议对4项提案达成共识。
- 共20项提案达成共识,1项未达成共识。
关键数值与推荐
- 投票采用9分制(1-3不同意,4-6既不同意也不反对,7-9同意)。
- 调查中共识定义为不同意票(1-3)低于15%。
- 共识会议中共识定义为不同意票低于30%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 仍需更多研究,尤其是关于叶酸以及儿童和脆弱患者等亚群甲氨蝶呤给药的提案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: A clear dosing regimen for methotrexate in psoriasis is lacking, and this might lead to a suboptimal treatment. Because methotrexate is affordable and globally available, a uniform dosing regimen could potentially optimize the treatment of patients with psoriasis worldwide. OBJECTIVE: To reach international consensus among psoriasis experts on a uniform dosing regimen for treatment with methotrexate in adult and pediatric patients with psoriasis and identify potential future research topics. DESIGN, SETTING, AND PARTICIPANTS: Between September 2020 and March 2021, a survey study with a modified eDelphi procedure that was developed and distributed by the Amsterdam University Medical Center and completed by 180 participants worldwide (55 [30.6%] resided in non-Western countries) was conducted in 3 rounds. The proposals on which no consensus was reached were discussed in a conference meeting (June 2021). Participants voted on 21 proposals with a 9-point scale (1-3 disagree, 4-6 neither agree nor disagree, 7-9 agree) and were recruited through the Skin Inflammation and Psoriasis International Network and European Academy of Dermatology and Venereology in June 2020. Apart from being a dermatologist/dermatology resident, there were no specific criteria for participation in the survey. The participants worked mainly at a university hospital (97 [53.9%]) and were experienced in treating patients with psoriasis with methotrexate (163 [91.6%] had more than 10 years of experience). MAIN OUTCOMES AND MEASURES: In a survey with eDelphi procedure, we tried to reach consensus on 21 proposals. Consensus was defined as less than 15% voting disagree (1-3). For the consensus meeting, consensus was defined as less than 30% voting disagree. RESULTS: Of 251 participants, 180 (71.7%) completed all 3 survey rounds, and 58 participants (23.1%) joined the conference meeting. Consensus was achieved on 11 proposals in round 1, 3 proposals in round 2, and 2 proposals in round 3. In the consensus meeting, consensus was achieved on 4 proposals. More research is needed, especially for the proposals on folic acid and the dosing of methotrexate for treating subpopulations such as children and vulnerable patients. CONCLUSIONS AND RELEVANCE: In this eDelphi consensus study, consensus was reached on 20 of 21 proposals involving methotrexate dosing in patients with psoriasis. This consensus may potentially be used to harmonize the treatment with methotrexate in patients with psoriasis.
引用
- van Huizen AM, Menting SP, Gyulai R, et al. International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. JAMA Dermatol. 2022. PMID: 35353175. doi:10.1001/jamadermatol.2022.0434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。